Up next
Author
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

Building Greater Supply-Chain Resiliency: What Are Leading Experts Saying?
By

Executives at DCAT Week’s education programs will address the industry’s most pressing challenges: inflationary pressures, supply-chain disruptions in a post-pandemic environment, and geopolitical and economic uncertainty. Hear from leading experts who will provide practical insights to address these challenges, including new tools/approaches to identify and mitigate supply risk.

Executives at DCAT Week’s education programs will address the industry’s most pressing challenges: inflationary pressures, supply-chain disruptions in a post-pandemic environment, and geopolitical and economic uncertainty. Hear from leading experts who will provide practical insights to address these challenges, including new tools/approaches to identify and mitigate supply risk. 

Changing customer-supplier expectations
How has the normal course of business between customers and suppliers changed in light of recent market volatility (inflationary pressures, supply-chain disruptions, and geopolitical uncertainty)?

Speaking at the DCAT Week Executive Insights program are (left to right): David Freidinger, Vice President, Business Management, Pharma Solutions, BASF Corporation; Wim Celen, Managing Director and Partner, Boston Consulting Group; Steve Kirk, Global Chief of Procurement, Catalent Pharma Solutions; Karin Shanahan, Executive Vice President, Global Product Development & Supply, Bristol-Myers Squibb

During DCAT Week, senior executives rom Bristol-Myers Squibb, Catalent, and BASF will share their perspectives on these recent changes. Executive Insights: Weathering the Storm – The Path Forward in Optimizing Supply Practices will address these all-important questions:

  • What are the new best practices and approaches in contracting? 
  • How has supplier evaluation and selection been affected?
  • What are the risk-mitigation strategies needed now and how can we anticipate the ones that will be necessary in the future? 

The program will be held at the InterContinental Barclay Hotel, Grand Ballroom on Tuesday, March 21, 2023: 10:30 – 11:45 AM; Doors open at 10:00 AM for coffee & networking.   

Register or learn more about the program here.  

Out-of-industry views
How are other industries dealing with the unprecedented supply-chain challenges of today?  The Disruption Busters: New Approaches in Supplier Risk Assessment & Mitigation, presented at DCAT Week, will provide expert insight from the automotive, tech, and other industries on new approaches/tools in supplier risk assessment and mitigation to build greater supply-chain resiliency. 

The program features executives from the management-consulting firm, Kearney (formerly A.T. Kearney) and the firms’ Center for Supplier Risk Management, and the Axia Institute, a research and education center of Michigan State University (MSU), with whom DCAT partnered with for this program. The Axia Institute was founded by leaders in value-chain creation and development at MSU, including the Broad College of Business, which is recognized for its top-ranked Supply Chain Management Program (U.S. News & World Report, 2022). DCAT is also a partner with MSU’s Broad College of Business and its top-ranked Supply Chain Management Program.  

The Disruption Busters: New Approaches in Supplier Risk Assessment & Mitigation  will be held at the InterContinental Barclay Hotel, Grand Ballroom on Wednesday, March 22, 2023: 10:15 AM – 11:30 AM. 

Register or learn more about this program here.     

A C-suite view on sustainability

Lisa Martin,
Senior Vice President, Global Procurement, and Chief Procurement Officer,
GlaxoSmithKline

Sustainability has become an all-important issue in bio/pharma companies’ selection and evaluation of their suppliers as companies seek to reduce their carbon footprint in line with international climate goals. But what are bio/pharma companies expecting from their suppliers, and how can suppliers meet those expectations?

GlaxoSmithKline’s (GSK) Chief Procurement Officer (CPO), Lisa Martin, will provide a C-suite view of sustainability at the DCAT Week education program, Industry Radar 2023: Energy, Raw Materials & Sustainability. She will discuss GSK’s sustainable procurement program for suppliers and how it is working with suppliers to meet the company’s environmental targets in emissions, water usage, and waste reduction. The program will provide practical insights on how your company can meet its sustainability targets in its sourcing and supply practices, and for suppliers, the program provides a customer-centric view on what it takes to be a valued partner in sustainability. 

The program will also examine another hot-button issue in 2023: rising input costs by providing an energy and chemicals outlook to see the pressure points in raw materials costs and what can be expected in 2023 and the near term. 

The program will be held at the InterContinental Barclay Hotel, Grand Ballroom on Tuesday, March 21, 2023: 2:00 PM – 3:15 PM; Doors open at 1:30 PM for coffee & networking.

Register or learn more about this program here. 

Recent Feature Articles

The CDMO/CMO Report: Cell and Gene Therapies
By

By
Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.

Pharma Innovation: AI in Drug Manufacturing
By

By
What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.

Pharma Industry Outlook: What Lies Ahead?
By

By
With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

ROI in Pharma R&D Falls in Post-Pandemic Market
By

By
A recent analysis by the management consultancy firm, Deloitte, shows that the bio/pharma industry’s return on investment (ROI) in R&D has fallen in the post-pandemic market. Projected ROI in pharma R&D in 2022 fell to 1.2%, the lowest ROI observed in the 13 years since the firm has conducted the study.